A year makes all the difference. In March 2011, the FDA sent Amyvid (florbetapir) back to its manufacturer, Avid Radiopharmaceuticals Inc., a wholly owned subsidiary of Eli Lilly and Co. Inc., of Indianapolis, to develop a reader training program for interpretation of scans made with Amyvid.